Abstract
East, South, and Southeast Asia (together referred to as Southeastern Asia hereafter) have been recognized as critical areas fuelling the global circulation of seasonal influenza. However, the internal migration network of seasonal influenza within Southeastern Asia remains unclear, including how pandemic-related disruptions altered the network structure and circulation dynamics in this region. Here, we leveraged genetic, epidemiological, and airline travel data between 2007-2023 to characterise the multiyear dispersal patterns of influenza A/H3N2 and B/Victoria viruses both out of and within Southeastern Asia, including during seasons marked by perturbations such as the 2009 A/H1N1 and COVID-19 pandemics. We show consistent Autumn-Winter movement waves of A/H3N2 and B/Victoria from Southeastern Asia to temperate regions during interpandemic seasons. During the COVID-19 pandemic this trend was interrupted for both subtypes, however the A/H1N1 pandemic only disrupted A/H3N2 spread. For influenza strains circulating in Southeastern Asia, we find a higher persistence of A/H3N2 than B/Victoria. We find pandemic-related disruptions in A/H3N2 antigenic evolution, with a greater time-advanced antigenic evolution during the 2009 A/H1N1 pandemic, and a greater time-lagged pattern during the COVID-19 pandemic, compared to inter-pandemic levels. Internally, in comparison to the interpandemic seasons, the inferred dispersal rates within Southeastern Asia decreased by 54.7% and 79.2% during the 2009 A/H1N1 and COVID-19 pandemic seasons, respectively; further, the internal movement structure within Southeastern Asia markedly diverged during the COVID-19 pandemic season, and to a lesser extent, during the 2009 A/H1N1 pandemic season. Analyses of the trunk location and phylogenetic similarity further reveal a temporally varying pattern within Southeastern Asia, suggesting a complex source-sink network, with a notable decrease in the mixing of lineages around the COVID-19 pandemic season. Our findings provide insights into the heterogeneous interplay between influenza circulation in Southeastern Asia and two distinct pandemic-related disruptions (strong decline in human movements during the COVID-19 pandemic, pronounced pathogen interference during the A/H1N1 pandemic), which can help anticipate the effects of potential mitigation strategies and the emergence of future influenza pandemic strains on influenza dynamics.
Competing Interest Statement
H.Y. received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang, Shanghai Roche Pharmaceutical Company, and SINOVAC Biotech Ltd. None of these funds are related to this work. All other authors declare no competing interests.
Funding Statement
H.Y. acknowledges financial support from the Key Program of the National Natural Science Foundation of China (No. 82130093) and the General Program of the National Natural Science Foundation of China (No. 82073613). M.U.G.K. acknowledges funding from The Rockefeller Foundation, Google.org, the Oxford Martin School Pandemic Genomics programme, European Union's Horizon Europe programme projects MOOD (#874850) and E4Warning (#101086640), the John Fell Fund, a Branco Weiss Fellowship and Wellcome Trust grants 225288/Z/22/Z, 226052/Z/22/Z & 228186/Z/23/Z, United Kingdom Research and Innovation (#APP8583) and the Medical Research Foundation (MRF-RG-ICCH-2022-100069). P.L. acknowledges support from the European Research Council (grant agreement no. 725422 ReservoirDOCS) and from the Research Foundation Flanders (Fonds voor Wetenschappelijk Onderzoek Vlaanderen, G0D5117N, G005323N and G051322N). Z.C. acknowledges financial support from the National Natural Science Foundation of China (No. 823B2089). J.C. acknowledges financial support from the Young Scientists Fund of the National Natural Science Foundation of China (No. 82304199). The contents of this publication do not necessarily reflect the views of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† These authors jointly supervised this work
Data Availability
All data produced in the present study are available upon reasonable request to the authors